- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Urothelial Tract Cancer - March 2002
National Cancer Institute®
Last Modified: March 1, 2002
Table of Contents
1
UI - 11748366
AU - Kim TS; Seong DH; Ro JY
TI -
Small cell carcinoma of the ureter with squamous cell and transitional
cell carcinomatous components associated with ureteral stone.
SO - J Korean Med Sci 2001 Dec;16(6):796-800
AD - Department of Pathology, Inha University College of Medicine, Inchon,
Korea. tskim@inha.ac.kr
We report a case of primary small cell carcinoma of the ureter with
squamous cell and transitional cell carcinomatous components associated
with ureteral stone, which is unique in that the patient has remained
free of tumor recurrence for 36 months after the surgery without
adjuvant chemotherapy or radiotherapy. A 60-yr-old man presented himself
with a right flank pain. Computed tomography revealed an ill-defined
mass and a stone in the lower one third of the right ureter, and
hydronephroureterosis above the stone-impacted site. The patient
underwent right nephroureterectomy and stone removal. Upon gross
examination, a 3.8 x 1.8 x 1.2 cm white and partly yellow mass was noted
in the anterior part of the ureter, resulting in indentation of the
ureteral lumen on the posterior side. Light microscopic examination
revealed that the mass was mainly composed of small cell carcinoma, and
partly squamous cell and transitional cell carcinomatous components. The
overlying ureteral mucosa and renal pelvis also contained multifocal
dysplastic transitional epithelium and transitional cell carcinoma in
situ. There was no vascular invasion, and the surgical margins were free
of tumor. The small cell carcinomatous component was positive for
chromogranin, neuron specific enolase, synaptophysin, and pancytokeratin
but negative for high molecular-weight cytokeratin (K-903) by
immunohistochemistry.
2
UI - 11797592
AU - Altwein JE
TI -
[Dysuria. Typical symptoms for proper diagnosis]
SO - MMW Fortschr Med 2001 Nov 26;143 Suppl():121-30; quiz 131-2
AD - Urologische Abteilung, Krankenhaus der Barmherzigen Bruder, Munchen.
3
UI - 11685715
AU - Gow KW; Hoffer F; Lasater O; Shochat SJ
TI -
Intraureteral Wilms tumor.
SO - J Pediatr Surg 2001 Nov;36(11):1729-30
AD - Department of Surgery & Radiology, St Jude Children's Research Hospital,
Memphis, TN, USA.
4
UI - 11868382
AU - Kakoi N; Miyajima A; Motizuku T; Mizuguchi Y; Asano T; Hayakawa M
TI -
[Carcinosarcoma of the renal pelvis and ureter: a case report]
SO - Hinyokika Kiyo 2002 Jan;48(1):29-32
We report a case of carcinosarcoma of the renal pelvis and ureter
arising in an 89-year-old man who presented at our hospital with gross
hematuria. Abdominal computed tomography, excretory pyelography, and
retrograde pyelography demonstrated that left hydronephrosis was caused
by an ureteral tumor. Left urine cytology indicated transitional cell
carcinoma. The patient underwent chemotherapy and radiation therapy.
However, gross hematuria recurred, and the patient underwent left
nephroureterectomy. The surgical specimen showed carcinosarcoma in the
renal pelvis and ureter histologically. He has been free of cancer for
1.5 years.
5
UI - 11550496
AU - Gyurkovics E; Nagy Z; Pajor L; Sipos B; Szucs M; Harsanyi L
TI -
[Successfully operated infraperitoneal hemangiopericytoma infiltrating
the left ureter]
SO - Magy Seb 2001 Aug;54(4):253-5
AD - Semmelweis Egyetem Altalanos Orvostudomanyi Kar I. sz. Sebeszeti
Klinika, 1082 Budapest, Ulloi ut 78. ge@seb1.sote.hu
Hemangiopericytoma is a very rare tumour originating from the lining
cells of small vessels. Despite benign histology it is clinical
presentation similar to malignancy. There are only less than hundred
cases reported sporadically in the literature. Authors report a case and
successful radical removal of an infraperitoneal hemangiopericytoma
infiltrating the left ureter. The literature of this strange, rare
pathology is also analysed in the article.
6
UI - 11844814
AU - Vaughn DJ; Broome CM; Hussain M; Gutheil JC; Markowitz AB
TI -
Phase II trial of weekly paclitaxel in patients with previously treated
advanced urothelial cancer.
SO - J Clin Oncol 2002 Feb 15;20(4):937-40
AD - University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA.
djv@mail.med.upenn.edu
PURPOSE: We evaluated the efficacy and toxicity of weekly paclitaxel in
patients with previously treated advanced urothelial cancer. PATIENTS
AND METHODS: Patients with urothelial cancer who had received one prior
systemic chemotherapy regimen for advanced disease and had evidence of
disease progression were eligible for enrollment. Patients received
paclitaxel 80 mg/m(2) by 1-hour intravenous infusion weekly. A cycle of
therapy consisted of four weekly treatments. RESULTS: The study enrolled
31 patients. Mean age was 66 years, and 45% of patients had three or
more involved metastatic sites. Only 26% of patients had responded to
prior chemotherapy. The median number of cycles delivered was three
(range, one to eight) at a mean weekly paclitaxel dose of 79 mg/m(2).
Three patients achieved a partial response (10%; 95% confidence
interval, 0% to 20%). Median time to progression was 2.2 months, and
median overall survival time was 7.2 months. Therapy was well tolerated
with minimal hematologic toxicity. Grade 3 nonhematologic toxicities
were also uncommon. CONCLUSION: Although the overall response rate to
weekly paclitaxel in patients with previously treated advanced
urothelial cancer was modest, the chemotherapy-refractory nature of the
study population should be considered.
7
UI - 11111187
AU - Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N;
TI -
Takahara S; Okuyama A
Bacillus Calmette-Guerin perfusion therapy for the treatment of
transitional cell carcinoma in situ of the upper urinary tract.
SO - Eur Urol 2000 Dec;38(6):701-4;discussion 705
AD - Department of Urology, Osaka University Medical School, Suita City,
Osaka, Japan. nono@uro.med.osaka-u.ac.jp
OBJECTIVES: The aim of this study is to evaluate the efficacy and safety
of intrarenal bacillus Calmette-Guerin (BCG) instillation as a treatment
for transitional cell carcinoma in situ (CIS) of the upper urinary
tract. METHODS: Diagnostic criteria of upper urinary tract CIS were (1)
positive urinary cytology, (2) negative multiple random biopsy of the
bladder and prostatic urethra, (3) negative radiographic findings in the
upper urinary tract and (4) two serial positive cytologies in selective
ipsilateral urine sampling from the pyeloureteral system. Eleven
patients diagnosed as having upper urinary tract CIS were enrolled in
this study. Thus, 11 renal units were treated with BCG instillation.
After placing a 6-french Double-J stent, BCG (80 mg) in 40 ml saline was
instilled into the bladder weekly, 6 times in total as one course.
RESULTS: At the end of one course, 9 cases showed negative urinary
cytology. Among these 9 cases, 2 showed recurrence in the upper urinary
tract after 4 months and 8 months of disease-free interval,
respectively. These 2 cases have received an additional course of BCG
instillation, but the urinary cytology did not normalize. Mean
recurrence-free time was 19.6 months. Of the other 7 cases who responded
to the first course of instillation, 6 cases were alive with no evidence
of the disease. The remaining patient died of rectal cancer with no
evidence of transitional cell carcinoma (TCC). Of the 2 cases who showed
positive urinary cytology even after the first course, 1 underwent
nephroureterectomy. The other case was diagnosed as having malignant
lymphoma 3 months after the end of this instillation therapy, and he
died of malignant lymphoma. As side effects, 8 cases (72.7%) showed
bladder irritability, and 4 presented fever higher than 38 degrees C.
However, no patient needed antitubercular treatment. CONCLUSION: As for
the short-term response, BCG instillation for the treatment of upper
urinary tract CIS is considered to be effective and safe. Longer
follow-up and further experience with this treatment are required.
8
UI - 11888084
AU - Witte D; Truong LD; Ramzy I
TI -
Transitional cell carcinoma of the renal pelvis the diagnostic role of
pelvic washings.
SO - Am J Clin Pathol 2002 Mar;117(3):444-50
AD - Department of Pathology, Baylor College of Medicine and the Methodist
Hospital, Houston, TX 77030, USA.
One hundred renal pelvic washings were reviewed blindly for 12 cytologic
features. Of 52 washings with tissue confirmation, the cytologic
diagnosis suggestive of or positive for transitional cell carcinoma
(TCC) was made in 36 cases; 11 were negative, and 5 were unsatisfactory.
Of 36 positive washings, histology confirmed the TCC diagnosis in 35 but
revealed only reactive changes in 1. Of 11 negative washings, 9 were
histologically negative for TCC, and 2 were positive for high-grade TCC.
Among 48 washings without tissue confirmation, 33 were negative for TCC
or showed reactive changes, 12 were negative for high-grade dysplasia or
malignancy, but low-grade TCC could not be ruled out, 1 was suggestive
of malignancy, and 2 were unsatisfactory. Clinical follow-up revealed no
TCC. Predictive cytologic features of high-grade TCC were high
nuclear/cytoplasmic ratio, isolated cells, anisonucleosis, nuclear
hyperchromasia, and coarse chromatin; for low-grade they were presence
of more than 5 papillary groups, cellular overlapping, anisonucleosis,
and hyperchromasia. The sensitivity and specificity for the cytologic
diagnosis were 89% and 97% for high-grade TCC and 100% and 78% for
low-grade TCC, respectively. Renal pelvic washings can be used to
accurately diagnose TCC of the renal pelvis. The positive predictive
value for high-grade TCC is 93%, but for low-grade tumors it is 43%.
9
UI - 11851772
AU - Hisataki T; Takahashi A; Taguchi K; Shimizu T; Suzuki K; Takatsuka K;
TI -
Iwaki H
Sarcomatoid transitional cell carcinoma originating from a duplicated
renal pelvis.
SO - Int J Urol 2001 Dec;8(12):704-6
AD - Department of Urology, Sunagawa City Medical Center, Sunagawa, Japan.
hisataki@sapmed.ac.jp
A case of sarcomatoid transitional cell carcinoma of the renal pelvis is
reported. It was distinguished from carcinosarcoma by
immunohistochemical study. The tumor was difficult to distinguish from a
renal parenchymal tumor in imaging studies because it originated from a
duplicated renal pelvis.
10
UI - 11868087
AU - Bellin MF; Springer O; Mourey-Gerosa I; Coumbaras J; Chartier-Kastler E;
TI -
Delcourt A; Beigelman C; Grenier P
CT diagnosis of ureteral fibroepithelial polyps.
SO - Eur Radiol 2002 Jan;12(1):125-8
AD - Department of Radiology, Groupe Hospitalier Pitie-Salpetriere, 75651
Paris, France. marie-france.bellin@pbr.ap-hop-paris.fr
We report a case of fibroepithelial polyp of the ureter with serial CT
examinations. Progressive growth of the fibroepithelial polyp was
documented by CT within a period of 62 months. Excretory phase
contrast-enhanced CT images accurately contributed to the diagnosis of
ureteral fibroepithelial polyp and allowed limited surgical resection.
Accurate imaging assessment of ureteral fibroepithelial polyps is
essential for a conservative surgical approach and/or observation alone.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
